Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Stephen F Thompson"'
Autor:
Lynda J. Krasenbaum, Vasantha L. Pedarla, Stephen F. Thompson, Krishna Tangirala, Joshua M. Cohen, Maurice T. Driessen
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background Following approval of fremanezumab for the prevention of migraine in adults, health care decision makers are interested in understanding real-world clinical characteristics and treatment patterns among patients initiating fremanez
Externí odkaz:
https://doaj.org/article/62fa09b7fa36471dad994913a5d193fd
Autor:
Maurice T. Driessen, Joshua M. Cohen, Stephen F. Thompson, Oscar Patterson-Lomba, Michael J. Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu, Rajeev Ayyagari
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-12 (2022)
Abstract Background Fremanezumab, a fully humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine in adults. The efficacy and safety of fremane
Externí odkaz:
https://doaj.org/article/459b359bd0684724bbb509f6d2b6cb05
Autor:
Maurice T. Driessen, Joshua M. Cohen, Oscar Patterson-Lomba, Stephen F. Thompson, Michael Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu, Rajeev Ayyagari
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-15 (2022)
Abstract Background The efficacy and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of migraine in adults, hav
Externí odkaz:
https://doaj.org/article/12dd913a8637410284ba9557236c8ce7
Autor:
Stephen D. Silberstein, Shoshana Reshef, Joshua M. Cohen, Sanjay Gandhi, Michael Seminerio, Verena Ramirez Campos, Yoel Kessler, Stephen F. Thompson, Andrew Blumenfeld
Publikováno v:
Advances in Therapy. 40:445-459
Through 2018, three calcitonin gene-related peptide pathway-targeted monoclonal antibodies (CGRP mAbs) had received US Food and Drug Administration (FDA) approval for migraine prevention: erenumab, fremanezumab, and galcanezumab.This retrospective an
Autor:
Hartmut Link, Stephen F. Thompson, Marc Tian, Jennifer S. Haas, Dominic Meise, Christopher Maas, Stamen Dimitrov
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 30(11)
We assessed the occurrence of neutropenia and febrile neutropenia (FN) and the associated healthcare resource in cancer patients receiving myelosuppressive chemotherapy in combination with pegfilgrastim versus lipegfilgrastim.This is a retrospective
Autor:
Ivy W. Kam, Şerban R. Iorga, Stephen F Thompson, Hsiao-Ching Huang, Dean G. Karalis, Kristen M.J. Azar, Matthew K. Ito, Robert J. Romanelli
Publikováno v:
Journal of clinical lipidology. 14(3)
Background A better understanding of patterns in statin utilization and low-density lipoprotein cholesterol (LDL-C) among patients with atherosclerotic cardiovascular disease (ASCVD) in a clinical practice setting is needed. Objectives The objective
Publikováno v:
Journal of Allergy and Clinical Immunology. 113:415-419
Background Although clinical trials have demonstrated that rhinitis therapy improves subjective and objective measures of asthma, it is uncertain whether treatment of allergic rhinitis significantly affects the frequency of asthma exacerbations. Obje
Autor:
Bradley G. Somer, Arthur C. Houts, Daniel Hennessy, Mark S. Walker, PJ Miller, Leonardo Viana Nicacio, Stephen F Thompson
Publikováno v:
The Journal of community and supportive oncology. 12(9)
Background Treatment for metastatic castrate-resistant prostate cancer in community settings is not well understood. Objective To examine treatment patterns, sequencing, and outcomes in patients receiving second- and third-line treatment after first-
Publikováno v:
Journal of Clinical Oncology. 33:765-765
765 Background: To assess the economic impact of the availability of ziv-aflibercept for patients with mCRC following disease progression after oxaliplatin, a user-adaptable budget impact model was developed for payers, based on use of 5-fluorouracil
Autor:
Hongwei Wang, Sean Redmond, Andrew W. Lee, Eileen Fonseca, Stephen F Thompson, Sheikh Usman Iqbal, Gregory P. Hess, Ravinder Dhawan
Publikováno v:
Blood. 122:1580-1580
Introduction The prevalence of myelofibrosis (MF) is 3.6 to 5.6 cases per 100,000 in the United States. Overall median survival is 3 years and 1.3 years for patients with intermediate-2 and high-risk disease, respectively. The MF PracticE-Based Netwo